We are live on ! Find out more
VMI

VHCP Management III Portfolio holdings

AUM $504M
1-Year Est. Return 683.12%
This Fund
S&P 500
This Quarter Est. Return
+50.19%
1 Year Est. Return
+683.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$132M
AUM Growth
–
Cap. Flow
+$113M
Cap. Flow %
85.57%
Top 10 Hldgs %
98.61%
Holding
13
New
13
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$20.6M
2
TCDA
Tricida, Inc. Common Stock
TCDA
+$19.1M
3
KALV
KalVista Pharmaceuticals
KALV
+$17.4M
4
OBSV
ObsEva SA Ordinary Shares
OBSV
+$17M
5
ECYT
Endocyte, Inc. Common Stock
ECYT
+$10.3M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 92.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALV
1
DELISTED
KalVista Pharmaceuticals
KALV
$28.4M 21.47%
+1,284,931
New +$17.4M
BCRX icon
2
BioCryst Pharmaceuticals
BCRX
$2.28B
$23.4M 17.65%
+3,061,091
New +$20.6M
OBSV
3
DELISTED
ObsEva SA Ordinary Shares
OBSV
$20.9M 15.8%
+1,159,789
New +$17M
TCDA
4
DELISTED
Tricida, Inc. Common Stock
TCDA
$19.9M 15.02%
+650,585
New +$19.1M
ECYT
5
DELISTED
Endocyte, Inc. Common Stock
ECYT
$10.7M 8.05%
+600,000
New +$10.3M
KNSA icon
6
Kiniksa Pharmaceuticals
KNSA
$5.8B
$8.36M 6.32%
+327,777
New +$6.37M
KDMN
7
DELISTED
Kadmon Holdings, Inc.
KDMN
$7.98M 6.03%
+2,388,572
New +$8.47M
MRNS
8
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$6.72M 5.08%
+168,068
New +$4.78M
BLPH
9
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$2.46M 1.86%
+151,625
New +$3.6M
MTVA
10
MetaVia Inc
MTVA
$7.33M
$1.79M 1.35%
+13
New +$3.63M
APLS
11
DELISTED
Apellis Pharmaceuticals
APLS
$894K 0.68%
+50,290
New +$930K
CCXI
12
DELISTED
ChemoCentryx, Inc.
CCXI
$493K 0.37%
+39,036
New +$470K
CNST
13
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$449K 0.34%
+66,667
New +$635K

Similar funds

BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return

VHCP Management III's Q3 2018 Portfolio in Review

Q3 2018 is the first quarter with a 13F filing on record for VHCP Management III, which disclosed 13 positions worth $132M. Its ten largest holdings account for 99% of the portfolio.

Its largest position is BioCryst Pharmaceuticals: 3,061,091 shares worth $23.4M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets.

  • VHCP Management III's largest Q3 2018 buy was BioCryst Pharmaceuticals: 3,061,091 shares worth $23.4M.
  • VHCP Management III's ten largest holdings make up 99% of its $132M portfolio in Q3 2018.
  • VHCP Management III disclosed 13 positions in Q3 2018, its first 13F filing on record.

Based on VHCP Management III's 13F filing for Q3 2018, filed 13 Nov 2018.